The production of tolerance to human erythrocytes in the rat with cytosine arabinoside or cyclophosphamide. II. Previously immunized animals
Gordon, R.O.; Santanelli, J.P.; Wade, M.E.
Journal of Immunology 106(3): 865-867
1971
ISSN/ISBN: 0022-1767 PMID: 5547303 Document Number: 31673
Document emailed within 1 workday
Related Documents
Rose, W.C.; Trader, M.W.; Laster, W.R.; Schabel, F.M. 1978: Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide Cancer Treatment Reports 62(9): 1337-1349Bodey, G.P.; Rodriguez, V.; Hart, J.; Freireich, E.J. 1970: Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271) Cancer ChemoTherapy Reports 54(4): 255-262
Harakati, M.S. 1999: Cytosine arabinoside, mitoxantrone, and etoposide in the treatment of adult patients with previously untreated acute myeloid leukemia Saudi Medical Journal 20(4): 291-295
Takemoto, Y.; Sampi, K.; Kuraishi, Y.; Okabe, K.; Tamura, K.; Mizoguchi, H.; Saito, H.; Masaoka, T.; Ogawa, M. 1999: A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. the KRN8602 Leukemia Study Group International Journal of Hematology 70(1): 20-25
Whitecar, J.P.; Bodey, G.P.; Freireich, E.J.; McCredie, K.B.; Hart, J.S. 1972: Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults Cancer ChemoTherapy Reports 56(4): 543-550
Arlin, Z.; Case, D.C.; Moore, J.; Wiernik, P.; Feldman, E.; Saletan, S.; Desai, P.; Sia, L.; Cartwright, K. 1990: Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group Leukemia 4(3): 177-183
Hines, J.D.; Mazza, J.J.; Oken, M.M.; Bennett, J.M.; Adelstein, D.J.; Keller, A.; O'Connell, M.J. 1985: High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase i Pilot Study for the Eastern Cooperative Oncology Group Seminars in Oncology 12(2 Suppl 3: 117-119
Nagatoshi, Y.; Okamura, J.; Ikuno, Y.; Akamatsu, M.; Tasaka, H. 1997: Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children International Journal of Hematology 65(3): 269-275
Nutter, R.L.; Rapp, F. 1973: The effect of cytosine arabinoside on virus production in various cells infected with herpes simplex virus types 1 and 2 Cancer Research 33(1): 166-170
Bury, R.W.; Keary, P.J. 1978: Determination of cytosine arabinoside in human plasma by high-pressure liquid chromatography Journal of Chromatography 146(2): 350-353
Seleznev, I.V.; Lil'in, E.T.; Drozdov, E.S.; Nesvizhskiĭ, I.V.; Borisova, L.V. 1986: Action of ethanol introduced into a culture of human lymphocytes on the cytogenetic effect of cytosine arabinoside Genetika 22(5): 885-888
Osugi, Y.; Keisei, K.H.; Murayama, N.; Inoue, M.; Ishihara, S.; Hara, J.; Yagi, K.; Tawa, A.; Okada, S.; Izumi, Y. 1990: Effects of recombinant human granulocyte colony stimulating factor following high-dose cytosine arabinoside therapy in children with malignancy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(7): 1379-1382
Majlessipour, F.; Kwock, R.; Martin-Aragon, S.; Weinberg, K.I.; Avramis, V.I. 2001: Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities Anticancer Research 21(1a): 11-22
Baran, Y.; Gunduz, U.; Ural, A.U. 2006: Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine Experimental Oncology 28(2): 163-165
Roubal, J.; Závada, V.; Vejsada, J.; Boldogh, I.; Vonka, V. 1979: Effects of cytosine arabinoside on the incorporation of pyrimidine nucleosides into hamster cells transformed by herpes simplex type 1 and type 2 viruses and by human cytomegalovirus Acta Virologica 23(4): 314-318
Grant, S.; Traylor, R.; Bhalla, K.; Mccrady, C.; Pettit, G.R. 1992: Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells Leukemia 6(5): 432-439
Peterlejtner, E. 1978: Ophthalmic zoster treated with cytosine arabinoside Klinika Oczna 48(2): 71-72
Kufe, D.W.; Spriggs, D.R. 1985: Biochemical and cellular pharmacology of cytosine arabinoside Seminars in Oncology 12(2 Suppl 3: 34-48
Tatsumi, N.; Masaoka, T.; Ueda, Y.; Senda, N. 1970: Treatment of leukemia with cytosine arabinoside--on the intensification of remission Gan no Rinsho. Japan Journal of Cancer Clinics 16(7): 706-712
Derulska, D.; Rokicka-Milewska, R. 1975: Cytosine arabinoside in the treatment of acute leukemia in children Pediatria Polska 50(6): 723-728